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Abstract
The promising results of anaplastic lymphoma kinase (ALK) inhibitors have changed the significance of ALK fusions in
several types of cancer. These fusions are no longer mere research targets or diagnostic markers, but they are now directly
linked to the therapeutic benefit of patients. However, most available tumor tissues in clinical settings are formalin-fixed and
paraffin-embedded (FFPE), and this significantly limits detailed genetic studies in many clinical cases. Although recent
technical improvements have allowed the analysis of some known mutations in FFPE tissues, identifying unknown fusion
genes by using only FFPE tissues remains difficult. We developed a 59-rapid amplification of cDNA ends-based system
optimized for FFPE tissues and evaluated this system on a lung cancer tissue with ALK rearrangement and without the 2
known ALK fusions EML4-ALK and KIF5B-ALK. With this system, we successfully identified a novel ALK fusion, KLC1-ALK. The
result was confirmed by reverse transcription-polymerase chain reaction and fluorescence in situ hybridization. Then, we
synthesized the putative full-length cDNA of KLC1-ALK and demonstrated the transforming potential of the fusion kinase
with assays using mouse 3T3 cells. To the best of our knowledge, KLC1-ALK is the first novel oncogenic fusion identified
using only FFPE tissues. This finding will broaden the potential value of archival FFPE tissues and provide further biological
and clinical insights into ALK-positive lung cancer.
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Introduction
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase
that was discovered in anaplastic large-cell lymphoma (ALCL) in
the form of a fusion protein, NPM-ALK [1,2]. The formation of a
fusion protein with a partner through chromosomal translocations
is the most common mechanism of ALK overexpression and ALK
kinase domain activation. Recent promising results of clinical trials
with an ALK inhibitor, crizotinib, have changed the significance
of ALK fusions in lung cancer [3,4,5,6], inflammatory myofibro-
blastic tumors (IMTs) [7], and ALCL [8]. ALK fusions are no
longer mere research targets or diagnostic markers and are now
directly linked to the therapeutic benefit of patients.
In lung cancer, 3 fusion partners of ALK have been reported—
EML4, TFG, and KIF5B—although the presence of TFG-ALK in
lung cancer has not yet been proven with histopathological
evidence [9,10,11]. In addition to lung cancer, ALK has further
been found to generate fusions in ALCL (fused to NPM, TPM3,
TPM4, ATIC, TFG, CLTC, MSN, MYH9, or ALO17)
[1,2,12,13,14,15,16,17,18,19], IMT (TPM3, TPM4, CLTC,
CARS, RANBP2, ATIC, or SEC31A) [19,20,21,22,23,24],
ALK-positive large B-cell lymphoma (CLTC, NPM, SEC31A,
or SQSTM1) [25,26,27,28], and renal cancer (VCL, TPM3 or
EML4) (Table 1) [29,30]. In addition to TFG-ALK in lung cancer,
some ALK fusions have been reported without histopathological
evidence: TPM4-ALK in esophageal squamous cell carcinoma
[31,32] and EML4-ALK in colon and breast carcinomas [33].
Anti-ALK immunohistochemistry played an important role in
identifying these ALK fusion partners. Several ALK fusions exhibit
a characteristicstaining pattern inanti-ALKimmunohistochemistry
because the subcellular localization of ALK fusion proteins depends
on the fusion partner. For example, NPM-ALK, which is the most
common fusion in ALK-positive ALCL (85%), exhibits a nuclear
and cytoplasmic staining pattern because the heterodimer of NPM
and NPM-ALK localizes in the nucleus and the homodimer of
NPM-ALK in the cytoplasm; CLTC-ALK exhibits a cytoplasmic
granular pattern because it localizes in the small vesicles. If a tumor
exhibits an unrecognized anti-ALK staining pattern, the patient
may have a novel fusion partner. In addition to the difference in
subcellular localization, the difference in staining intensity is a keyto
identifying novel partners. EML4-ALK is hardly stained by
conventional anti-ALK immunohistochemistry [11,34]. To over-
come this limitation, we developed the intercalated antibody-
enhanced polymer (iAEP) method, which moderately increases
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EML4-ALK was consistently stained with this method [11]. This
indicated that a tumor that is positively immunostained for ALK
only by a sensitive immunohistochemistry method but not by
conventional methods may harbor a novel ALK fusion. Based on
this hypothesis, we successfully identified PPFIBP1-ALK in 2 IMT
cases that were positive in anti-ALK immunohistochemistry only
when stained by the iAEP method [35].
Anti-ALK immunohistochemistry may thus be useful to detect
candidate tumors for a novel ALK fusion. However, to identify the
fusion partner, other molecular techniques are usually required
such as 59-rapid amplification of cDNA ends (59-RACE) or inverse
reverse-transcription polymerase chain reaction (RT-PCR). To the
best of our knowledge, no novel oncogenic fusions have been
discovered using formalin-fixed paraffin-embedded (FFPE) tissues
only because nucleic acids extracted from FFPE tissues are
severely degraded during the fixation process. In the present study,
we developed a 59-RACE method optimized for ALK fusion
partner detection that was applicable to FFPE tissues and
identified a novel fusion, kinesin light chain 1 (KLC1)-ALK, in
lung cancer by using only an FFPE tissue.
Methods
Materials
A FFPE tissue block of pulmonary adenocarcinoma in situ,
nonmucinous (formerly called bronchioloalveolar carcinoma) [36],
which was excised from a 47-year-old female patient was used [37].
This carcinoma was negative for EML4-ALK and KIF5B-ALK,
although the presence of ALK rearrangement was confirmed by anti-
ALK iAEP immunohistochemistry and a split fluorescence in situ
hybridization (FISH) assay for ALK (hereafter referred to as the
unknownALKfusion-positive case)(Figure1) [37].Two FFPE tissue
blocks of ALK-positive tumor cases were also employed, for which
the presence of EML4-ALK or KIF5B-ALK had already been
confirmed.TotalRNAwasextractedfromeachFFPEtissuewiththe
use of the RecoverAll
TM Total Nucleic Acid Isolation Kit for FFPE
(Applied Biosystems Japan, Tokyo, Japan). The ages of the 3 FFPE
blocks used (time from FFPE tissue production to RNA extraction)
were 65, 40, and 51 months for the unknown ALK fusion-positive
case, EML4-ALK, and KIF5B-ALK, respectively. Written informed
consent was obtained from each patient. The study was approved by
the institutional review board of the Shizuoka Cancer Center
(approval ID 22-J132-22-1) and theJapanese Foundation for Cancer
Research (approval ID 2010-1011).
Modified 59-RACE for ALK fusions applicable to FFPE
tissues
59-RACE was performed with the SMARTer RACE cDNA
Amplification Kit (Clontech) according to the manufacturer’s
instruction with minor modifications. In brief, instead of the
primers included in the kit, ALK-3242R (59-CTCAGCTTG-
TACTCAGGGC-39) was used for cDNA synthesis. The cDNA
was subjected to 59-RACE PCR using PrimeSTAR HS DNA
Polymerase (TaKaRa) and the following primers: Universal
Primer A Mix of the kit and ALK-3206R (59-ATGGCTTG-
CAGCTCCTGGTGCTT-39). The PCR condition consisted of
5 cycles at 94uC for 30 s and 72uC for 3 min; 5 cycles at 94uC for
30 s, 70uC for 30 s, and 72uC for 3 min; and 30 cycles at 94uC for
30 s, 68uC for 30 s, and 72uC for 3 min.
FISH
FISH analysis of fusion genes was performed with DNA probes
for KLC1 and ALK. Unstained sections (4-mm thick) were
subjected to hybridization with an ALK-split probe set (Dako,
Tokyo, Japan) or with bacterial artificial chromosome (BAC)
clone-derived probes for ALK (RP11-984I21 and RP11-62B19)
Table 1. ALK fusion partners.
Reported year Partner Locus ALK+ALCL ALK+LBCL IMT NSCLC RCC
1994 NPM 5q35.1 ++
1999 TPM3 1p23 ++ +
1999 TFG 3q12.2 ++ *
2000 ATIC 2q35 ++
2000 TPM4 19p13 ++
2001 CLTC 17q23 +++
2001 MSN Xp11.1 +
2002 ALO17 17q25.3 +
2003 MYH9 22q13.1 +
2003 RANBP2 2q13 +
2003 CARS 11p15 +
2006 SEC31A 4q41 ++
2007 EML4 2p21 ++
2009 KIF5B 10p11.22 +
2011 SQSTM1 5q35.3 +
2011 PPFIBP1 12p11 +
2011 VCL 10q22.2 +
Present study KLC1 14q32.1 +
*Histopathological evidence is lacking. Abbreviations: ALCL, anaplastic large cell lymphoma; LBCL, large B-cell lymphoma; IMT, inflammatory myofibroblastic tumor;
NSCLC, non-small cell lung carcinoma; RCC, renal cell carcinoma.
doi:10.1371/journal.pone.0031323.t001
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with DAPI and examined using a BX51 fluorescence microscope
(Olympus, Tokyo, Japan).
Synthesis of the putative cDNA of KLC1-ALK
Two independent PCRs were performed using cDNA synthesized
from a tumor tissue expressing KIF5B-ALK with the following
primer sets: KLC1-NheI-M (59-GCGCTAGCGAATGTATGAC-
AACATGTCCAC-39) and KLC1-bpR (59-GTGCTTCCGGCGG-
TACACATCTACAGAACCAAACTC-39), and ALK-bpF (59-G-
GGAGTTTGGTTCTGTAGATGTGTACCGCCGGAAGC-39)
and ALK-EcoRI (59-GATAGAATTCTCAGGGCCCAGGCT-39).
Then, the second PCR was performed using a 1/100 dilution of a
mixture of the firstPCRproductsas a template with the KLC1-NheI-
M and ALK-EcoRI primers (Figure 2).
Transformation assay for KLC1-ALK
Analysis of the transforming activity of kinase fusions was
performed as described previously [9,38,39]. A pMXS-based
expression plasmid for each fusion was used to generate
recombinant ecotropic retroviruses [40], which were then used
individually to infect mouse 3T3 fibroblasts. The formation of
transformed foci was evaluated after culturing the cells for 4 days.
The same set of 3T3 cells was injected subcutaneously into nu/nu
mice, and tumor formation was examined after 14 days. The
animal experiments were approved by the animal ethics
committee of Jichi Medical University (approval ID 1135).
Results
Identification of KLC1-ALK as a novel ALK fusion gene
Our modified 59-RACE faithfully isolated cDNA fragments for
EML4-ALK or KIF5B-ALK from known ALK- positive tumors
(Supplementary Figure S1A and B). We then attempted to isolate
cDNA fragments encompassing the fusion points from the
unknown ALK fusion-positive case. Nucleotide sequencing of
such 59-RACE products revealed that 2 of 10 clones contained the
39-terminus of exon 9 of KLC1 (ENST00000348520) fused to the
first nucleotide of exon 20 of ALK (ENST00000389048), indicating
the presence of a novel fusion between KLC1 and ALK. As this
rearrangement constituted an in-frame fusion between the 2 genes,
the full-length KLC1-ALK cDNA probably produces a protein of
984 amino acids containing an amino-terminal two-thirds of
KLC1 and an intracellular region of ALK (Figure 3A). RT-PCR-
mediated isolation of a fusion point successfully confirmed the in-
frame fusion between the 2 messages (Figure 3A and B). Further,
to confirm the genomic rearrangement responsible for the fusion,
a fusion FISH assay was performed (Figure 3C). These results were
consistent with the presence of t(2;14)(p23;q32.3), leading to the
generation of KLC1-ALK.
Transforming potential of KLC1-ALK
The putative full-length cDNA of KLC1-ALK was synthesized
from the frozen tissue with KIF5B-ALK fusion expression
(Figure 2, Supplementary Figure S2), and was used to generate
a recombinant retrovirus expressing the fusion protein with an
amino-terminal FLAG epitope tag. Infection of 3T3 cells with the
virus expressing KLC1-ALK readily produced multiple trans-
formed foci in culture and subcutaneous tumors in a nude mouse
tumorigenicity assay (Figure 4), confirming the potent transform-
ing ability of KLC1-ALK.
Discussion
Here, by analyzing the FFPE tissues only, we successfully
discovered a novel ALK fusion, KLC1-ALK. While snap-frozen
materials sampled from biopsied or surgically removed specimens
Figure 1. ALK-rearranged lung adenocarcinoma without EML4-ALK and KIF5B-ALK. Panel A shows the results of anti-ALK
immunohistochemistry with the iAEP method on pulmonary adenocarcinoma in situ, nonmucinous. The staining pattern was diffusely cytoplasmic.
The basal side of tumor cells was more strongly stained, indicating an uneven subcellular localization of KLC1-ALK protein. FISH analyses revealed
that this case was positive in the split assay for ALK (Panel B: individual 59- and 39-signals are observed) and negative in EML4-ALK and KIF5B-ALK
fusion assays (Panel C: EML4, red; ALK, green; Panel D: KIF5B, green; ALK, red).
doi:10.1371/journal.pone.0031323.g001
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routinely sampled in most clinical settings. In contrast, FFPE
specimens are usually produced, and histopathology diagnostic
archives are an extremely large resource of FFPE tissues in
ordinary diagnostic pathology laboratories. However, DNA and
RNA extracted from FFPE tissues are severely degraded during
formalin fixation and are usually not suitable for assays that need
long DNA/RNA of high quality. Recent technical advances have
allowed some analyses for known point mutations and known
fusion genes, but it is still difficult to identify an unrecognized gene
aberration using only an FFPE tissue.
In most ALK fusions, the break point of ALK is located within
intron 19, and the fusion point in mRNA is typically the first
nucleotide of exon 20. Therefore, if the primers for 59-RACE are
placed immediately downstream of the first nucleotide of ALK
exon 20, such 59-RACE may successfully isolate PCR products
containing the partner gene sequence even using FFPE tissues.
Based on this hypothesis, we established a 59-RACE system for
ALK fusions optimized for FFPE tissues. With this system, we
identified a novel ALK fusion, KLC1-ALK. To the best of our
knowledge, this is the first novel oncogenic fusion identified using
only an FFPE tissue.
Caution, however, is needed. In some rare cases with ALK
fusion, the break point of ALK fusion mRNA may not be at the 59-
end of exon 20. For example, in variant 4 of EML4-ALK, exon 14
of EML4 is fused to an unknown sequence of 11 bp, which in turn
is connected to nucleotide 50 of ALK exon 20 (E14;in-
s11;del49A20) [38]. Our 59-RACE system would not work on
such a case because the reverse primer ALK-3206R corresponds
to nucleotides 12–34 of ALK exon 20. Therefore, if our modified
59-RACE fails to isolate fusion cDNAs from cases with a
confirmed ALK rearrangement, other primer settings may be
attempted.
Kinesin is a heterotetramer of 2 kinesin heavy chains and 2
kinesin light chains, and it moves on the microtubules towards
their plus ends carrying various cargos. The heavy chains harbor
the motor activity, whereas the light chains play roles in cargo
binding and in modulating the activity and subcellular localization
of the heavy chains. KLC1 binds to the kinesin heavy chains with
an N-terminal domain and to various cargos via the tetratricopep-
tide repeat domains [41,42]. Of the 3 histopathologically
confirmed ALK fusion partners in lung cancer, EML4 colocalizes
with microtubules and may contribute to the stabilization of
microtubules [43], KIF5B moves on the microtubules as a kinesin
heavy chain [44], and KLC1 binds to kinesin heavy chains as a
kinesin light chain. Therefore, it is interesting that all the 3 ALK
fusions in lung cancer are likely to colocalize with microtubules.
The most frequent ALK fusion in lung cancer is EML4-ALK
(4–7%) [9,38], and the second is KIF5B-ALK (0.5%) [11]. One
case with TFG-ALK is reported [10]. KLC1-ALK may be rare
but exists in lung adenocarcinoma, and the patients with this
fusion are highly likely to benefit from ALK inhibitor therapy as
do patients with other ALK fusions. The incidence may be low,
but the significance of this fusion is very high from the perspective
Figure 2. Synthesis of the putative KLC1-ALK full-length cDNA. Two first-round PCRs were performed separately using cDNA synthesized
from a tumor tissue expressing KIF5B-ALK with the following primer sets: KLC1-NheI-M and KLC1-bpR, and ALK-bpF and ALK-EcoRI. KLC1-bpR and
ALK-bpF had sequences downstream of the ALK break point (exon 20) and upstream of the KLC1 break point (exon 9) as adopter sequences,
respectively. Then, the second PCR was performed using a 1/100 dilution of the mixture of the first PCR products as a template with primers KLC1-
NheI-M and ALK-EcoRI. The first PCR products were annealed, extended with each other, and then amplified with the primers.
doi:10.1371/journal.pone.0031323.g002
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important point is that KLC1-ALK was found in adenocarcinoma
in situ, nonmucinous (formerly called bronchioloalveolar carcino-
ma, BAC). BAC is recognized to rarely harbor ALK fusions,
although a small number of BAC cases has been examined for
ALK fusion compared with invasive adenocarcinoma. It would be
interesting from a pathobiological perspective to examine a large-
scale cohort of BAC and other premalignant conditions for ALK
fusion.
There are 3 methods for the detection of ALK fusions: RT-
PCR, ALK split FISH, and high-sensitivity anti-ALK immuno-
histochemistry. For RT-PCR, the 59 partner gene must be known.
Our findings in this study identified one more partner gene that
should be targeted in ALK-fusion detection using RT-PCR in lung
cancer. The other 2 methods can detect all ALK fusions regardless
of fusion partner and, therefore, are suitable for ALK-fusion
screening. In other words, these 2 methods cannot identify the
fusion partner and need to be succeeded by partner-specific RT-
PCR and/or fusion FISH for this purpose. If it is revealed that the
partner gene in the tested case is unknown, a novel partner gene is
highly likely to be discovered, as was shown in the present study.
In fact, using high-sensitivity anti-ALK immunohistochemistry
(iAEP method) as screening, we have identified several novel ALK
fusions in various types of cancers including lung adenocarcinoma
[11], lymphoma [28], sarcoma [35], and renal cell carcinoma
[30].
Many efficient tools have been established for the detection of
ALK fusion-positive cases using FFPE tissues, including anti-ALK
immunohistochemistry and FISH. Our findings will further
expand the potential value of archival FFPE tissues and provide
further biological and clinical insights into ALK-positive cancers in
the forthcoming era of ALK inhibitor therapy.
Figure 3. Identification of KLC1-ALK. Panel A shows the schematic structure of KLC1, ALK, and KLC1-ALK proteins and the cDNA sequence
around the fusion point. Dark blue, orange, and red parts represent coiled-coil, transmembrane, and kinase domains, respectively. The break point
exons and the number of amino acids are indicated. KLC1-ALK-specific RT-PCR using RNA extracted from the FFPE tissue of the unknown ALK fusion-
positive case amplified a fragment of the expected product size (140 bp, Panel B) with the consistent fusion sequence (Panel A). A fusion FISH assay
for KLC1-ALK revealed a fusion signal (yellow) in multiple tumor cells (Panel C). M, marker (100-bp ladder); S, sample (the unknown ALK fusion-positive
case); N, no template control.
doi:10.1371/journal.pone.0031323.g003
Figure 4. Transforming potential of KLC1-ALK. Upper panels:
Mouse 3T3 fibroblasts were infected with retroviruses encoding KLC1-
ALK or EML4-ALK or with the corresponding empty virus (Mock). The
cells were photographed after 4 days of culture. Scale bar, 1 mm. Lower
panels: Nude mice were injected subcutaneously with the correspond-
ing 3T3 cells, and tumor formation was examined after 14 days. The
number of tumors formed per injections is indicated at the bottom.
doi:10.1371/journal.pone.0031323.g004
KLC1-ALK in Lung Cancer
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Figure S1 59-RACE products using FFPE tissues. Our
modified 59-RACE faithfully isolated cDNA fragments for EML4-
ALK (A) or KIF5B-ALK (B) from known ALK- positive tumors.
(TIF)
Figure S2 Putative cDNA sequence of KLC1-ALK. The
putative full-length cDNA of KLC1-ALK was synthesized from the
frozen tissue with KIF5B-ALK fusion expression.
(PDF)
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